Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 19/20 | 1.00 |
| ▸ | FKBP5 | Q13451 | 8/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807412 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL13694681 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL619873 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL29410221 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15049130 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15049129 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL20983469 | 0.98 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL10034617 | 0.94 | FKBP1A (0.90) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL18089279 | 0.94 | FKBP1A (0.89) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL16683539 | 0.94 | FKBP1A (0.89) | FKBP1AFKBP5FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607352-A1 | Pipecolate-diketoamides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-26 | — | — | EP | claimed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3331905-B1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA FARBER CANCER INST INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | NEW YORK UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11293023-B2 | Tunable endogenous protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-2607352-A1 | Pipecolate-diketoamides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20130123134-A1 | SMALL MOLECULE PRINTING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-7932213-B2 | Solid phase synthesis with benzylidene linker attaching compound on glass slide; microarrays; drug screening | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932213-B2 | Solid phase synthesis with benzylidene linker attaching compound on glass slide; microarrays; drug screening | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-04-26 | — | — | US | disclosed |
| WO-2010077317-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20090221433-A1 | SMALL MOLECULE PRINTING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-03 | — | — | US | disclosed |
| WO-2008013569-A2 | SMALL MOLECULE PRINTING | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | FKBP1A 572/4885FKBP5 394/4885FKBP4 906/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | FKBP1A 224/4885FKBP5 443/4885FKBP4 508/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | FKBP1A 73/4885FKBP5 203/4885FKBP4 301/4885 |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | MDM2, UBE3C, CUL1 | FKBP1A 327/4885FKBP5 670/4885FKBP4 728/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | FKBP1A 1184/4885FKBP5 1835/4885FKBP4 2298/4885 |
| US-11293023-B2 | Tunable endogenous protein degradation | PSMG3, MYCBP, DBN1 | FKBP1A 34/4885FKBP5 98/4885FKBP4 158/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | FKBP1A 1386/4885FKBP5 1087/4885FKBP4 2178/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | FKBP1A 34/4885FKBP5 98/4885FKBP4 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.